Prime Medicine Strikes $3.5B Deal for T-Cell Therapy Advances

Prime Medicine, Inc. ( (PRME) ) has issued an update.

Prime Medicine, Inc. has announced a significant collaboration with Bristol Myers Squibb to usher in a new era of ex vivo T-cell therapies. Through this deal, Prime Medicine will receive an upfront payment and equity investment totaling $110 million, with the potential to earn over $3.5 billion in milestone payments plus royalties. The alliance leverages Prime Medicine’s Prime Editing technology, aiming to develop treatments for immunological diseases and cancer, addressing areas with high unmet medical needs.

For detailed information about PRME stock, go to TipRanks’ Stock Analysis page.